Cover Image
市場調查報告書

菲律賓的醫藥品、醫療產業分析

Philippines Pharmaceuticals and Healthcare Report Q4 2017

出版商 BMI Research 商品編碼 177615
出版日期 內容資訊 英文 97 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
菲律賓的醫藥品、醫療產業分析 Philippines Pharmaceuticals and Healthcare Report Q4 2017
出版日期: 2017年10月11日 內容資訊: 英文 97 Pages
簡介

本報告提供菲律賓的製藥、醫療產業結構和最新趨勢相關分析,今後10年的產業規模的動向估計,產業的課題 (風險) 和未來商機 (利潤) 相關評估,政府的政策、規定,競爭環境,主要企業簡介等資訊彙整,為您概述為以下內容。

BMI的見解

SWOT分析

產業預測

  • 醫藥品市場預測
  • 醫療市場預測
  • 處方藥市場預測
  • 專利藥市場預測
  • 學名藥市場預測
  • 一般用醫藥品 (成藥) 市場預測
  • 醫藥品貿易的預測

產業的風險/利潤、等級

  • 亞太地區:風險/利潤、等級
  • 菲律賓:風險/利潤、等級
    • 利潤
    • 風險

法規

  • 知識產權問題
  • 價格設定的體制
  • 醫療費償付的體制

市場概況

  • 醫療部門
  • 醫療保險
  • 臨床實驗
  • 流行病學

競爭環境

  • 研究開發意向型產業
  • 學名藥品廠商
  • 醫藥品的流通
  • 醫藥品的零售部門

企業簡介

人口結構的預測

詞彙表

分析方法

  • 醫藥品支出額的預測模式
  • 醫療費的預測模式
  • 分析方法的相關注記
  • 風險/利潤、等級技術

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1748-376X

BMI View: Generic drugmakers will be the primary beneficiaries of the Philippine government's investment into healthcare. While the expansion of universal healthcare is positive for the broader pharmaceutical sector, the specific target of the 2017 budget is to expand healthcare access to low-income Filipinos. Moreover, the constraints on affordability and the demand for low-cost pharmaceuticals will spur greater investment from drugmakers with strong generic drug portfolios. Innovative drugmakers will continue to face significant challenges due to the Philippines' weak intellectual property protection and its market access barriers.

Headline Expenditure Projections:

  • Pharmaceuticals: PHP156.2bn (USD3.38bn) in 2016, rising to PHP162.3bn (USD3.23bn) in 2017; +3.9% in local currency terms and -4.4% in US dollar terms.
  • Healthcare: PHP722.9bn (USD15.65bn) in 2016, rising to PHP794.9bn (USD15.83bn) in 2017; +10.0% in local currency terms and +1.2% in US dollar terms.

Latest Updates:

  • In August 2017, the Department of Health (DOH) was criticised after it announced plans to cut the maintenance and operating budgets of 49 public hospitals by 28.5%, amounting to PHP1.49bn (USD30mn), as part of the proposed budget allocation for 2018.

Table of Contents

BMI Industry View

  • Table: Headline Pharmaceuticals & Healthcare Forecasts (Philippines 2015-2021)

SWOT

Industry Forecast

  • Pharmaceutical Market Forecast
    • Table: Pharmaceutical Sales, Historical Data And Forecasts (Philippines 2013-2021)
  • Healthcare Market Forecast
    • Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2013-2021)
    • Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2013-2021)
    • Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2013-2021)
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Philippines 2013-2021)
  • Patented Drug Market Forecast
    • Table: Patented Drug Market Indicators, Historical Data And Forecasts (Philippines 2013-2021)
  • Generic Drug Market Forecast
    • Table: Generic Drug Market Indicators, Historical Data And Forecasts (Philippines 2013-2021)
  • OTC Medicine Market Forecast
    • Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Philippines 2013-2021)
  • Pharmaceutical Trade Forecast
    • Table: Pharmaceutical Trade Data And Forecasts (Philippines 2015-2021)
    • Table: Pharmaceutical Trade Data And Forecasts local currency (Philippines 2015-2021)

Industry Risk/Reward Index

  • Asia Pacific Pharmaceuticals: Diverse Opportunities And Inherent Risks
  • Philippines Risk/Reward Index
  • Regulatory Review
  • Intellectual Property Issues
  • Pricing Regime
  • Reimbursement Regime

Market Overview

  • Healthcare Sector
    • Table: Healthcare Resources (Philippines 2011-2016)
    • Table: Healthcare Personnel (Philippines 2011-2016)
    • Table: Healthcare Activity (Philippines 2011-2016)
  • Health Insurance
  • Clinical Trials
  • Epidemiology

Competitive Landscape

  • Research-Based Industry
    • Table: Multinational Market Activity
  • Generic Drugmakers
  • Pharmaceutical Distribution
  • Pharmaceutical Retail Sector
    • Table: Overview Of BnB, BNB and P100 Programme
    • Table: Cost Of Generic Drugs In Philippines (PHP)
    • Table: Number Of BnBs And BNBs In Selected Philippine Regions

Company Profile

  • GlaxoSmithKline Philippines
  • Novartis
  • Demographic Forecast
    • Table: Population Headline Indicators (Philippines 1990-2025)
    • Table: Key Population Ratios (Philippines 1990-2025)
    • Table: Urban/Rural Population & Life Expectancy (Philippines 1990-2025)
    • Table: Population By Age Group (Philippines 1990-2025)
    • Table: Population By Age Group % (Philippines 1990-2025)

Glossary

Methodology

  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
    • Table: Indicators - Rationale And Sources
Back to Top